Your session is about to expire
← Back to Search
CBL0137 for Extremity Melanoma or Sarcoma
Study Summary
This trial is testing a new drug (CBL0137) to see what the best dose is and what the side effects are in patients with cancer that has spread to their extremities.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Treatment (CBL0137)
Frequently Asked Questions
What kind of risks does FACT Complex-targeting Curaxin CBL0137 carry for individuals undergoing treatment?
"Considering the preliminary nature of this Phase 1 trial, Power assigned FACT Complex-targeting Curaxin CBL0137 a score of 1 in terms of safety. This reflects the limited data available for assessing its efficacy and security."
Is enrollment still open for this research experiment?
"Affirmative. According to clinicaltrials.gov, this trial is actively seeking candidates for participation as of March 18th 2022 and was initially advertised on July 1st 2019. The experiment necessitates 36 volunteers from a single site in order to be completed successfully."
What is the scope of the clinical trial participants?
"Affirmative. On clinicaltrials.gov, it is stated that this medical trial is actively requiring participants; the original post was made on July 1st 2019 and last updated March 18th 2022. The study seeks to recruit 36 individuals from a single site."
Share this study with friends
Copy Link
Messenger